Twice-Yearly Biologic Dosing Sets New Bar for Severe Asthma Management

GlaxoSmithKline's EXDENSUR (depemokimab) received FDA approval on December 16, 2025, as an add-on maintenance therapy for severe eosinophilic asthma in adults and pediatric patients aged 12 and older -- a twice-yearly subcutaneous dosing schedule that will require manufacturing and fill-finish teams to revisit long-cycle biologic storage, cold-chain integrity, and patient adherence protocols across the supply chain.

The approval was supported by two identically designed, 52-week, randomized, double-blind, placebo-controlled trials -- SWIFT-1 (NCT04719832) and SWIFT-2 (NCT04718103) -- enrolling 762 patients across 331 sites in 23 countries. Eligible patients carried a documented asthma diagnosis of at least two years, with inadequate symptom control despite medium- to high-dose inhaled corticosteroids plus at least one additional controller agent. The primary endpoint measured annualized exacerbation rates requiring systemic corticosteroids, hospitalization, or emergency department visits over 52 weeks. EXDENSUR was administered at 100 mg once every six months.

For QA and regulatory teams, the six-month dosing interval introduces sterility assurance and container closure integrity considerations that differ materially from monthly or quarterly biologics. A single administration failure carries proportionally greater clinical consequence when the next scheduled dose is six months away. Process validation strategies for prefilled delivery systems and extended in-use stability data will warrant close scrutiny during any post-approval inspection readiness review under 21 CFR Part 211 and ICH Q10 quality system expectations.

Trial geography and demographic scope: Twenty-five percent of the 762 enrolled patients were from the United States; the remaining 75% were enrolled internationally across sites including Australia, Canada, China, France, Germany, Japan, and the United Kingdom, among others. The breadth of the trial geography will inform post-market pharmacovigilance obligations across multiple regulatory jurisdictions simultaneously.

Source: FDA Drug Trials Snapshots -- EXDENSUR, published April 28, 2026, based on original approval data from December 16, 2025. Refer to the EXDENSUR Prescribing Information for all approved conditions of use.